Cytokinetics CEO Robert I. Blum disposes of $471,600 in common shares
CYTK•Cytokinetics CEO Robert I. Blum exercised options for 7,500 shares at $10.60 and sold 7,500 shares at $62.88 on Oct. 12, 2026.
1. Share transactions
Blum exercised options for 7,500 Cytokinetics shares at $10.60 each and sold 7,500 shares at $62.88 each on Oct. 12, 2026. His directly held common stock position fell to 278,544 shares, and his directly held non-qualified stock options declined to 141,745.
